← All trials
NCT05056558
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- Sep 24, 2021
- Last posted
- Sep 28, 2021
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Incepta Vaccine LimitedLead sponsor
- Bangladesh Medical UniversityOverall official - principal investigator
- Dhaka Medical CollegeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.